Teva Pharmaceutical Industries
TEVA
#671
Rank
A$53.48 B
Marketcap
A$46.62
Share price
-1.10%
Change (1 day)
32.37%
Change (1 year)

P/E ratio for Teva Pharmaceutical Industries (TEVA)

P/E ratio as of January 2026 (TTM): 50.3

According to Teva Pharmaceutical Industries's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 50.2698. At the end of 2024 the company had a P/E ratio of -15.2.

P/E ratio history for Teva Pharmaceutical Industries from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2024-15.2-31.57%
2023-22.2416.35%
2022-4.30-120.41%
202121.1
2019-10.760.27%
2018-6.65470.31%
2017-1.17-100.23%
20165011393.06%
201533.5127.09%
201414.8-38.26%
201323.9

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Novartis
NVS
19.6-60.95%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
12.4-75.39%๐Ÿ‡ซ๐Ÿ‡ท France
GSK plc
GSK
13.4-73.43%๐Ÿ‡ฌ๐Ÿ‡ง UK
Pfizer
PFE
14.9-70.40%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
14.3-71.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Dr. Reddy's Laboratories
RDY
15.9-68.42%๐Ÿ‡ฎ๐Ÿ‡ณ India
AstraZeneca
AZN
29.8-40.69%๐Ÿ‡ฌ๐Ÿ‡ง UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.